Techniques for producing universal humanized CAR19-DNT cells and their uses

Universal CAR19-DNT cells address the limitations of current CAR-T therapies by providing a low-cost, safe, and effective treatment for CD19-positive tumors through large-scale production without TCR gene knockout, enhancing accessibility and safety.

JP7595241B2Active Publication Date: 2024-12-06ZHEJIANG RUIJIAMEI BIOTECH CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2022563458
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-04-20
Filing Date
2021-04-14
Publication Date
2024-12-06
Estimated Expiration
2041-04-14

AI Technical Summary

Technical Problem

Current CAR-T cell therapies for cancer, such as CD19-targeted CART cells, face challenges including high production costs, complex manufacturing processes, potential viral gene transduction into tumor cells, graft-versus-host disease, and severe side effects like cytokine storms, limiting their accessibility and efficacy.

Method used

Development of universal CAR19-DNT cells derived from healthy donors, which do not require TCR gene knockout, are less immunogenic, and have a long survival time, using a method that allows for large-scale production and low-cost manufacturing, targeting CD19 with a specific CAR construct.

Benefits of technology

The CAR19-DNT cells effectively target CD19-positive tumors with high specificity and safety, avoiding graft-versus-host disease and reducing production costs, making them a viable off-the-shelf treatment option for various cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595241000001
    Figure 0007595241000001
  • Figure 0007595241000002
    Figure 0007595241000002
  • Figure 0007595241000003
    Figure 0007595241000003
Patent Text Reader

Abstract

The present invention provides a technology for producing and using universal humanized CAR19-DNT cells. Specifically, the present invention provides universal CAR-T cells targeting CD19, expressing an exogenous CAR construct. The CAR construct has a structure represented by Formula I: L-scFv-H-TM-C-CD3ζ (Formula I), where L is absent or a signal peptide sequence, scFv is a single-chain variable region sequence of an antibody targeting CD19, H is absent or a hinge region, TM is a transmembrane domain, C is a costimulatory signal molecule, and CD3ζ is an intracellular signaling sequence derived from CD3ζ. The universal humanized CAR19-DNT cells provided by the present invention have the advantages of low immunogenicity, no risk of GvHD caused by gene editing, high safety, high specificity, and significant tumor-killing effect. Furthermore, the provided construction method is feasible for large-scale production and low production costs.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the technical field of tumor immune cell therapy, specifically to a technical method for producing universal humanized chimeric antigen receptor CART-19 cells and its use. [Background technology]

[0002] Chimeric antigen receptor T (CART) is currently one of the most promising tumor immunotherapies, and two CART cell products have already been approved by the US FDA in 2017. Both are peripheral blood mononuclear cells (PBMCs) isolated from tumor patients themselves, and by introducing a specific antigen receptor (CAR) into PBMCs by genetic engineering, the targeting, killing activity, and durability of T cells are enhanced, and recognition of tumor cell surface antigens does not depend on MHC restriction. Common CARs consist of an extracellular antigen-binding region, a transmembrane region, and an intracellular T cell receptor signaling region (e.g., CD3ζ or CD28). The extracellular antigen-binding region consists of the light chain (VL) and heavy chain (VH) of a monoclonal antibody, and the middle is linked by a hinge to form a single chain antibody (single chain fragment variable, scFv), which can recognize specific tumor antigens. CAR-T cell technology has already developed to the third generation. The first generation CAR consists of a single-chain fragment (scFv) antigen-binding site that recognizes tumor surface antigens and an immune receptor tyrosine activation motif. Outside the cell, the single-chain fragment (scFv) recognizes tumor marker molecules, but due to the lack of a costimulatory signal, in clinical practice, there are problems such as a short survival time of T cells in the body and low cytokine secretion ability, and the effect is not good. The second generation CART technology introduces a costimulatory signal sequence, which can improve the cytotoxic activity, proliferation ability and survival time of T cells in the body, promote the release of cytokines, and has been successfully used in the treatment of acute lymphoblastic leukemia in clinical practice. The third generation CART has two costimulatory molecules, CD28 and 4-1BB, and CD3ζ molecules arranged in series in the cytoplasmic region, and the dual costimulatory signal sequence has a better effect. A schematic diagram of the structure of the third generation CART is shown in Figure 1.

[0003] Currently, autologous CART cells are used to treat B-cell acute lymphoblastic cell leukemia (B-ALL) by targeting CD19, with a high complete remission rate of over 90%. The complete remission rate is also high in the treatment of lymphoma, at 64%. The effectiveness of CART technology in treating these two diseases is unmatched by any other drug. In our country, acute lymphoblastic leukemia accounts for 80% of acute childhood leukemia, with an incidence rate of one in 100,000, and 20% of all adult leukemias. Immune cell therapy is an important treatment for many serious diseases, including cancer, autoimmune diseases, and even severe viral infections, and there are cases in which immune cell therapy has been successful.

[0004] Although CD19-targeted CART has shown remarkable efficacy in clinical trials, it has many drawbacks. In addition to severe side effects such as cytokine storm, there are four major problems: first, some terminal patients with low lymphocyte counts or poor quality lose the chance of CART treatment because they do not have enough autologous immune cells; second, it has been reported that when using CART products produced with the patient's autologous cells, viral genes are transduced into residual tumor cells in the peripheral blood, leading to the death of the patient; in addition, most of the general-purpose CART cell products currently under development use gene editing technology to knock out genes that can cause graft-versus-host disease, such as TCR receptors, but knocking out these genes requires complicated construction processes and large-scale sequencing, and has a high off-target rate; finally, the production of autologous CART cell products is a one-to-one individualized treatment, which has high production costs and complex manufacturing process requirements, making the products expensive and unaffordable for many patients, which increases the social medical burden.

[0005] Therefore, in this field, there is a strong need for the development of versatile (ready-to-use) CART cells and methods for constructing them that do not require complex gene editing methods to knock out the TCR genes that cause graft-versus-host disease from the peripheral blood of healthy donors, and that have low immunogenicity (do not trigger an anti-graft immune response in the host and have a long survival time in the body), high safety, significant killing effect, and low production costs. Summary of the Invention

[0006] In view of a series of problems in the existing related art, the present invention provides a technical method for producing universal chimeric antigen receptor CAR19-DNT cells and its use.

[0007] The object of the present invention is to provide a versatile (ready-to-use) CART cell that does not require complex gene editing methods to knock out the TCR gene that causes graft-versus-host disease from the peripheral blood of healthy donors, has low immunogenicity (does not induce an anti-graft immune response in the host and has a long survival time in the body), is highly safe, has a significant killing effect, and has low production costs, and a method for constructing the same.

[0008] In a first aspect of the present invention, there is provided a universal CD19-targeting CAR-T cell expressing an exogenous CAR construct, said CAR construct having a structure represented by formula I.

[0009] L-scFv-H-TM-C-CD3ζ (Formula I) (In the formula, L is either absent or a signal peptide sequence. scFv is an antibody single chain variable region sequence that targets CD19. H is absent or is the hinge region. TM is the transmembrane domain. C is a costimulatory signal molecule. CD3ζ is an intracellular signaling sequence derived from CD3ζ. Each "-" independently represents a connecting peptide or peptide bond connecting each of the above elements.

[0010] In another preferred embodiment, the CD19-targeting universal CAR-T cells are CD19-targeting universal CAR-double negative T cells (CAR-DNT cells).

[0011] In another preferred embodiment, the TCR in the universal CAR-T cell may or may not be knocked out.

[0012] In another preferred embodiment, the TCR in the universal CAR-T cell is knocked out.

[0013] In another preferred embodiment, the L is a signal peptide of a protein selected from the group consisting of CD8, GM-CSF, CD4, CD137, or a combination thereof.

[0014] In another preferred embodiment, L is a signal peptide derived from CD8.

[0015] In another preferred embodiment, the scFv comprises a heavy chain variable region (VH) having the amino acid sequence shown in SEQ ID NO:6 and a light chain variable region (VL) having the amino acid sequence shown in SEQ ID NO:5.

[0016] In another preferred embodiment, the scFv further comprises a connecting peptide sequence between the VH and VL.

[0017] In another preferred embodiment, the connecting peptide sequence has the amino acid sequence shown in SEQ ID NO:7.

[0018] In another preferred embodiment, the scFv has the amino acid sequence shown in SEQ ID NO:4.

[0019] In another preferred embodiment, the H is a hinge region of a protein selected from the group consisting of CD8, CD28, CD137, or a combination thereof.

[0020] In another preferred embodiment, the H is a hinge region derived from CD8.

[0021] In another preferred embodiment, the TM is a transmembrane region of a protein selected from the group consisting of CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, or a combination thereof.

[0022] In another preferred embodiment, the TM is a transmembrane region derived from CD8 and / or a transmembrane region derived from CD28.

[0023] In another preferred embodiment, the C is a costimulatory signal molecule selected from the group consisting of OX40, CD2, CD7, CD27, CD28, CD30, CD40, CD70, CD134, 4-1BB (CD137), PD1, Dap10, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), NKG2D, GITR, TLR2, or a combination thereof.

[0024] In another preferred embodiment, C is a 4-1BB-derived costimulatory signal molecule and / or a C28-derived costimulatory signal molecule.

[0025] In another preferred embodiment, the CAR construct has the amino acid sequence shown in SEQ ID NO:14.

[0026] In a second aspect of the invention, there is provided a method for producing a universal CD19-targeting CAR-DNT cell according to the first aspect of the invention, comprising the steps of: (i) providing an expression vector containing a nucleotide sequence encoding a CAR construct of formula I; L-scFv-H-TM-C-CD3ζ (Formula I) (In the formula, L is either absent or a signal peptide sequence. scFv is an antibody single chain variable region sequence that targets CD19. H is absent or is the hinge region. TM is the transmembrane domain. C is a costimulatory signal molecule. CD3ζ is an intracellular signaling sequence derived from CD3ζ. Each "-" independently represents a connecting peptide or peptide bond connecting each of the above elements. (ii) providing a DNT cell culture containing at least one DNT cell and transducing said DNT cell with the expression vector of step (i) to obtain a universal CAR-DNT cell targeting CD19 according to the first aspect of the invention; and (iii) detecting the reactive CAR-DNT cells obtained in optional step (ii). The present invention provides a method comprising:

[0027] In another preferred embodiment, the expression vector is selected from DNA, RNA, or a combination thereof.

[0028] In another preferred embodiment, the expression vector is selected from the group consisting of a plasmid, a viral expression vector, a transposon, or a combination thereof.

[0029] In another preferred embodiment, the viral expression vector is selected from the group consisting of a lentiviral vector, an adenoviral vector, a retroviral vector, or a combination thereof.

[0030] In another preferred embodiment, the expression vector is a viral expression vector, and the method further comprises, prior to step (ii), a step of performing viral packaging on the viral expression vector of step (i).

[0031] In another preferred embodiment, the viral expression vector is a retroviral expression vector or a lentiviral expression vector, preferably a lentiviral expression vector.

[0032] In another preferred embodiment, the polynucleotide sequence shown in SEQ ID NO:16 is incorporated into the viral expression vector in step (i).

[0033] In another preferred embodiment, the step (ii) comprises co-transfecting the viral expression vector in the step (i) with a packaging plasmid, psPAX2, pMD2.0G, into a viral packaging host cell.

[0034] In another preferred embodiment, in the step (i), the polynucleotide sequence comprises a nucleotide sequence encoding the scFv in formula (I) as shown in SEQ ID NO:15.

[0035] In another preferred embodiment, in the step (i), the polynucleotide sequence includes a nucleotide sequence encoding L in formula (I) as shown in SEQ ID NO:8.

[0036] In another preferred embodiment, in the step (i), the polynucleotide sequence comprises a nucleotide sequence encoding H in formula (I) as shown in SEQ ID NO:9.

[0037] In another preferred embodiment, in the step (i), the polynucleotide sequence comprises a nucleotide sequence encoding the TM in formula (I) as shown in SEQ ID NO:10.

[0038] In another preferred embodiment, in the step (i), the polynucleotide sequence comprises a nucleotide sequence encoding C in formula (I) as shown in SEQ ID NO:11.

[0039] In another preferred embodiment, in the step (i), the polynucleotide sequence comprises a nucleotide sequence encoding CD3ζ in formula (I) as shown in SEQ ID NO:12.

[0040] In another preferred embodiment, the viral packaging host cell is a mammalian cell, preferably a 293T cell.

[0041] In another preferred embodiment, before the step (ii), (iia) collecting a peripheral blood sample from a healthy donor; (iib) CD4 in peripheral blood samples + CD8 + obtaining DNT cells by removing T cells; (iic) A step of culturing and amplifying the DNT cells obtained in (iib) in a suitable medium in a culture flask coated with a CD3 monoclonal antibody to obtain a DNT cell-containing culture system required for step (ii). Includes.

[0042] In another preferred embodiment, the medium in step (iic) is supplemented with a substance selected from the group consisting of gentamicin, recombinant interleukin-2, recombinant interleukin-7, recombinant interleukin-12, recombinant interleukin-15, autologous plasma, AB serum, or a combination thereof.

[0043] In another preferred embodiment, the medium in step (iic) does not contain recombinant or wild-type human interleukin-4.

[0044] In another preferred embodiment, the medium in step (iic) does not contain AB serum.

[0045] In another preferred embodiment, the medium in step (iic) has a gentamicin concentration of 40-80 units / ml (preferably 60 units / ml), a recombinant human interleukin-2 concentration of 150-1000 IU / ml (preferably 200-250 IU / ml), a recombinant human interleukin-15 concentration of 5-20 ng / ml (preferably 10 ng / ml), a recombinant human interleukin-7 concentration of 1-5 ng / ml (preferably 2 ng / ml), a recombinant human interleukin-12 concentration of 5-20 ng / ml (preferably 10 ng / ml), a concentration of the autologous plasma of 3-25 v% (preferably 10-20 v%), and / or a concentration of the AB serum of 4-8 v% (preferably 6 v%).

[0046] In another preferred embodiment, in the step (ii), the concentration of DNT cells in the DNT cell culture medium is 1×10 6 cells / ml~4×10 6 cells / ml, preferably 1 x 10 6 cells / ml~2×10 6 cells / ml, more preferably 0.5×10 6 cells / ml~1×10 6 cells / ml.

[0047] In another preferred embodiment, in the step (ii), the MOI of the virus is 0.1 to 10, preferably 0.1 to 8, and more preferably 5.

[0048] In another preferred embodiment, the detection in step (iii) is carried out 7-14 days, preferably 8 or 13 days, after the transduction in step (ii).

[0049] In a third aspect of the present invention, (a) a universal CD19-targeting CAR-T cell according to the first aspect of the invention, and (b) A pharma- ceutically acceptable carrier, diluent or excipient. The present invention provides a pharmaceutical composition comprising:

[0050] In another preferred embodiment, the pharmaceutical composition is a liquid pharmaceutical composition.

[0051] In another preferred embodiment, the pharmaceutical composition is an injection.

[0052] In another preferred embodiment, the pharmaceutical composition comprises a concentration of the universal CAR-T cells targeting CD19 of 1×10 6 ~5×10 6 cells / mL, preferably 1 x 10 6 ~2×10 6 In cells / mL.

[0053] In a fourth aspect of the present invention, there is provided the use of a universal CD19-targeting CAR-T cell according to the first aspect of the present invention for the manufacture of a pharmaceutical composition or formulation for the prevention and / or treatment of cancer.

[0054] In another preferred embodiment, the tumor is selected from the group consisting of a hematological tumor, a solid tumor, or a combination thereof.

[0055] In another preferred embodiment, the tumor is a hematological tumor.

[0056] In another preferred embodiment, the hematological tumor is selected from the group consisting of acute myeloid leukemia (AML), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), or a combination thereof.

[0057] In another preferred embodiment, the solid tumor is selected from the group consisting of gastric cancer, gastric cancer peritoneal metastasis, liver cancer, leukemia, kidney tumor, lung cancer, small intestine cancer, bone cancer, prostate cancer, colorectal cancer, breast cancer, colon cancer, cervical cancer, ovarian cancer, lymphatic cancer, nasopharyngeal cancer, adrenal tumor, bladder tumor, non-small cell lung cancer (NSCLC), brain glioma, endometrial cancer, lung squamous cell carcinoma, anal cancer, head and neck tumor, or a combination thereof.

[0058] In a fifth aspect of the invention there is provided a method of preventing and / or treating a disease comprising administering to a subject in need thereof a generic CD19-targeted CAR-T cell as described in the first aspect of the invention, or a pharmaceutical composition as described in the third aspect of the invention.

[0059] In another preferred embodiment, the disease is cancer or a tumor.

[0060] In another preferred embodiment, the subject in need is a human or non-human mammal.

[0061] Of course, it is understood that within the scope of the present invention, the above technical features of the present invention and the technical features specifically described below (for example, in the Examples) can be combined with each other to form new or preferred technical solutions, which will not be described here one by one due to space limitations. [Brief description of the drawings]

[0062] [Figure 1] The structure of the third generation CART is shown. [Diagram 2] A structural schematic of the humanized CD19 CAR construct is shown. [Diagram 3] 3 shows a three-dimensional model of humanized CD19 with a mutation in the CDR1 domain (V27G). [Figure 4] On days 8 and 13 of culture, the proportion of DNT cells in the culture system identified by CD3, CD4, and CD8 antibody markers using a flow cytometer, the efficiency of infection of DNT cells with antibody gene-carrying lentivirus measured by specific anti-human CD19 variable region antibody marker, and the percentage of CART cells in the cell product calculated from these are shown. [Figure 5A]Figure 5 shows a comparison of in vitro specific tumor killing activity of humanized CAR19-DNT against Hela and Hela-CD19 target cells, respectively, on days 8 and 13 of culture. In Figure 5-A, real-time killing monitored by RTCA at an effector to target cell ratio of 2:1. Figure 5-B shows real-time killing monitored by RTCA 18 hours after effector cell addition at an effector to target cell ratio of 2:1. [Figure 5B] Figure 5 shows a comparison of in vitro specific tumor killing activity of humanized CAR19-DNT against Hela and Hela-CD19 target cells, respectively, on days 8 and 13 of culture. In Figure 5-A, real-time killing monitored by RTCA at an effector to target cell ratio of 2:1. Figure 5-B shows real-time killing monitored by RTCA 18 hours after effector cell addition at an effector to target cell ratio of 2:1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0063] The present inventor has conducted extensive and in-depth research and conducted a large amount of screening, and for the first time has developed a method for constructing universal chimeric antigen receptor CAR19-DNT cells. In experiments, the universal chimeric antigen receptor CAR19-DNT cells provided by the present invention do not require complex gene editing methods to knock out the TCR gene that causes graft-versus-host disease from the peripheral blood of healthy donors, and have the advantages of low immunogenicity (no immune response to the host's anti-graft and long survival time in the body), high safety, specific targeting of human CD19 antigen, and significant tumor killing effect, and the construction method provided by the present invention is feasible for large-scale production and has low production costs. Based on this, the present invention has been completed.

[0064] term To facilitate understanding of this disclosure, some terms are first defined. As used in this application, unless expressly defined otherwise herein, all of the following terms have the following meanings:

[0065] As used herein, the term "about" refers to a value or composition that is within an acceptable error range of a particular value or composition, as determined by one of ordinary skill in the art, which in part determines how the value or composition is measured or measured.

[0066] As used herein, the terms "administration" and "application" refer to the physical introduction of a product of the present invention into a subject by any one of a variety of methods and delivery systems known to those of skill in the art, including, but not limited to, intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other non-gastrointestinal routes of administration, such as by injection or infusion.

[0067] As used herein, the term "DNT cells" refers to double negative T cells, which have a unique phenotype: TCRαβ + and / or TCRγδ + T cells express CD3 molecules but do not express characteristic surface molecules (markers) of cells such as CD4, CD8, NK, and iNKT, and exert unique and diverse physiological functions in the body's immune system.

[0068] Double negative T (DNT) cells are CD3 + CD4 - CD8 -DNT cells are a subgroup of mature T lymphocytes, accounting for approximately 1-3% of peripheral blood mononuclear cells. They express CD3 molecules and αβ- or γδ-T cell receptors (TCR) on their surface, but differ from conventional T cells, NK cells, and NKT cells because they do not express CD4 or CD8 molecules and do not respond to invariant natural killer T (iNKT) cell-specific αGalCer. DNT cells exert cytotoxic and antigen-presenting functions through many of the body's natural mechanisms, while releasing cytokines / chemokines to activate a broader range of immune responses, making them candidates for a wide range of potential clinical therapeutic drugs.

[0069] The advantages of DNT cells as candidates for cellular immunotherapeutic drugs include the following. DNT cells can be used for many tumor indications, targeting the corresponding ligands expressed on many blood or solid tumors such as AML, lymphoma, cervical cancer, and lung cancer through receptors such as NKG2D and DNAM-1 on the cell surface, and secreting TNF-α, IFN-γ, Grazyme B, Peforin, IL-2, IL-4, etc. to exert direct and indirect tumor killing activity, and can be combined with immune checkpoint inhibitors such as PD-1, CTLA-4, and chemotherapeutic drugs to have synergistic therapeutic effects.

[0070] DNT cells are not restricted in their ability to kill tumor cells by MHC (major histocompatibility complex) molecules; heterologous DNT cells from healthy donors are injected into the patient's body without killing toxicity to normal cells in the patient's body, without affecting the further differentiation of hematopoietic stem cells, without leading to graft versus host disease (GvHD), and without host versus graft reactions; the injected heterologous DNT cells persist in the patient's body for a long time, thereby exerting tumor-killing activity.

[0071] DNT cells from healthy donors were efficiently cultured at 5 × 10 cells per ml of peripheral blood. 8The cells can be amplified to the above order, and after collection and cryopreservation, they can be used to treat multiple patients. Treatment can be performed once a patient is clearly diagnosed in clinical practice, and there is no need to wait for the production of products required for autologous CART products, making it a truly off-the-shelf, versatile (ready-to-use) cell product. In combination with the above-mentioned broad anti-tumor, high safety, universal and combination with other immunotherapies properties of DNT cells, in the present invention, a universal humanized chimeric antigen receptor CART-19 product targeting CD19 was designed, and then a series of universal CART cell products without the need for gene editing based on the DNT cell platform were developed.

[0072] Chimeric antigen receptors (CARs) Chimeric antigen receptors (CARs) consist of an extracellular antigen recognition domain, usually a single-chain variable fragment (scFv), a transmembrane domain and an intracellular costimulatory signal domain. The design of CARs has gone through the following process. The first generation of CARs has only one intracellular signal component, CD3ζ or FcγRI molecule, and only one activation domain in the cell, which can only cause short-term T cell proliferation and low cytokine secretion, but can provide long-term T cell proliferation signals and sustained anti-tumor effects in vivo, resulting in insufficient clinical therapeutic effects. The second generation of CARs is based on the original structure and introduces one costimulatory molecule, such as CD28, 4-1BB, OX40, and ICOS, which significantly improves the function compared to the first generation of CARs and further enhances the persistence of CAR-T cells and the killing ability of tumor cells. Based on the second generation of CARs, some new immune costimulatory molecules, such as CD27 and CD134, are tandemly linked, which has led to the development of third and fourth generation CARs.

[0073] The extracellular fragment of CAR recognizes one or more specific epitopes, and then transmits the corresponding signal through the intracellular domain, leading to cell activation and proliferation, cytotoxicity and secretion of cytokines, thereby eliminating the target cells. First, the patient's autologous or allogeneic (healthy donor) PBMCs are isolated, activated and genetically modified, and the CAR immune cells are generated. They are then infused into the patient's body, where they directly recognize and specifically kill the surface antigens of tumor cells without being restricted by MHC.

[0074] Specifically, the chimeric antigen receptor (CAR) of the present invention comprises an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain comprises a target-specific binding element (also called an antigen-binding domain). The intracellular domain comprises a costimulatory signaling region and / or a zeta chain portion. The costimulatory signaling region comprises a portion of the intracellular domain of a costimulatory molecule. A costimulatory molecule is a cell surface molecule that is required for an effective response of lymphocytes to antigens, and is not an antigen receptor or its ligand.

[0075] A linker may be introduced between the extracellular and transmembrane domains of the CAR, or between the intracellular and transmembrane domains of the CAR.

[0076] As used herein, the terms "linker" and "hinge region" generally refer to any oligopeptide or polypeptide that serves to link a transmembrane domain to the extracellular or intracellular domain of a polypeptide chain, but may be used interchangeably. A linker may contain 0-300 amino acids, preferably 2-100 amino acids, and most preferably 3-50 amino acids.

[0077] When the CAR of the present invention is expressed in immune cells, it can recognize antigens based on the specificity of antigen binding. Binding to the relevant antigen in tumor cells leads to the death of tumor cells, reducing or eliminating the tumor burden in patients. The antigen binding domain is preferably fused with one or more intracellular domains derived from costimulatory molecules and / or zeta chain. Preferably, the antigen binding domain is fused with the intracellular domain combined with CD28 costimulatory signal molecule, 4-1BB costimulatory signal molecule and CD3 zeta signal domain.

[0078] As used herein, the basic structure of the chimeric antigen receptor of the present invention comprises a tumor-associated antigen binding region, an extracellular hinge region, a transmembrane region, and an intracellular signal region. The selection of the tumor-associated antigen directly affects the therapeutic effect on the tumor. In the present invention, the chimeric antigen receptor of the present invention targets CD19.

[0079] CD19 is a transmembrane glycoprotein of approximately 95 kDa that is specific to the B cell lineage and is expressed primarily on early B cells. CD19 is expressed on both normal and malignant B cells and is considered to be the most reliable surface marker covering a long range of stages in the B cell development.

[0080] In one preferred embodiment of the present invention, an anti-CD19 single chain antibody is selected as the antigen-binding domain targeting CD19 in the CAR of the present invention.

[0081] In one preferred embodiment, the amino acid sequence of the scFv is shown in SEQ ID NO: 4 and efficiently binds to the CD19 molecule.

[0082] In the present invention, the antigen-binding domain targeting CD19 further includes a conservative variant of the scFv, and refers to a polypeptide in which, compared with the amino acid sequence of the scFv of the present invention, 10 or less, preferably 8 or less, more preferably 5 or less, and most preferably 3 or less amino acids are substituted with amino acids having similar or close properties. In the present invention, the number of added, deleted, modified and / or substituted amino acids is preferably 40% or less, more preferably 35% or less, more preferably 1 to 33%, more preferably 5 to 30%, more preferably 10 to 25%, and more preferably 15 to 20% of the total number of amino acids in the original amino acid sequence. In the present invention, the number of added, deleted, modified and / or substituted amino acids is usually 1, 2, 3, 4 or 5, preferably 1 to 3, more preferably 1 to 2, and most preferably 1.

[0083] Regarding the hinge region and transmembrane region (transmembrane domain), the CAR may be designed to include a transmembrane domain fused to the extracellular domain of the CAR. In one embodiment, a transmembrane domain associated with one of the domains in a naturally occurring CAR is used. In some instances, the transmembrane domain is selected or modified with amino acid substitutions to avoid binding of such domains to transmembrane domains of similar or different surface membrane proteins, thereby minimizing interactions with other members of the receptor complex.

[0084] Preferably, the CAR construct of the present invention has the structure CD8 lead sequence-CD19 scFv (VL-linker-VH)-CD8 hinge region-CD8 TM-41BB-CD3-ζ.

[0085] In one preferred embodiment, the amino acid sequence of the CAR of the present invention is represented by positions 1-489 of SEQ ID NO: 14. In addition, in the amino acid sequence of the CAR of the present invention that targets CD19, position 173 of SEQ ID NO: 14 corresponds to glycine (Gly).

[0086] Universal CAR-T cells targeting CD19 As used herein, the terms "CAR19-DNT cells", "universal CAR-DNT cells targeting CD19", "CAR-T cells of the invention", and "universal CAR-T cells of the invention" all refer to universal double negative T cells expressing a chimeric antigen receptor having the structure of formula I as described in the first aspect of the invention, which specifically targets the human CD19 molecule, and may be used interchangeably.

[0087] In the present invention, the CAR construct of the present invention is expressed in the CD19-targeting universal CAR-DNT cells.

[0088] Preferably, the TCR in the universal CAR-DNT cells targeting CD19 is knocked out.

[0089] Manufacturing method The present invention also provides a method for producing a universal CAR-DNT cell targeting CD19 of the present invention, comprising the steps of: (i) providing an expression vector containing a nucleotide sequence encoding a CAR construct of the invention; (ii) providing a DNT cell culture containing at least one DNT cell and transducing said DNT cell with the expression vector of step (i) to obtain a universal CD19-targeting CAR-DNT cell of the invention; and (iii) detecting the reactive CAR-DNT cells obtained in optional step (ii).

[0090] Preferably, the expression vector in the production method of the present invention is a viral expression vector, particularly preferably a lentiviral expression vector.

[0091] In addition, the following steps are required for obtaining the DNT cell culture medium in step (ii) of the method: (iia) collecting a peripheral blood sample from a healthy donor; (iib) CD4 in peripheral blood samples + CD8+ obtaining DNT cells by removing T cells; (iic) A step of culturing and amplifying the DNT cells obtained in (iib) in an appropriate medium in a culture flask coated with a CD3 monoclonal antibody to obtain a DNT cell-containing culture system required for step (ii).

[0092] Preferably, the culture medium in step (iic) is supplemented with a substance selected from the group consisting of gentamicin, recombinant interleukin-2, recombinant interleukin-7, recombinant interleukin-12, recombinant interleukin-15, autologous plasma, AB serum, or a combination thereof.

[0093] In another preferred embodiment, the medium in step (iic) has a gentamicin concentration of 40-80 units / ml (preferably 60 units / ml), a recombinant human interleukin-2 concentration of 150-100 IU / ml (preferably 200-250 IU / ml), a recombinant human interleukin-15 concentration of 5-20 ng / ml (preferably 10 ng / ml), a recombinant human interleukin-7 concentration of 1-5 ng / ml (preferably 2 ng / ml), a recombinant human interleukin-12 concentration of 5-20 ng / ml (preferably 10 ng / ml), a concentration of the autologous plasma of 3-25 v% (preferably 10-20 v%), and / or a concentration of the AB serum of 4-8 v% (preferably 6 v%).

[0094] In one preferred embodiment of the invention, the culture medium in step (iic) is free of recombinant or wild-type human interleukin-4 and is free of AB serum.

[0095] Drug Compositions The present invention provides a formulation comprising the CD19-targeting universal CAR-T cells according to the first aspect of the present invention and a pharma- ceutically acceptable carrier, diluent or excipient. In one embodiment, the pharmaceutical composition is a liquid formulation. Preferably, the formulation is an injectable formulation. Preferably, the formulation has a concentration of the CAR-T cells of 1×10 5 ~1×10 8 cells / mL, more preferably 1 x 10 5 ~1×10 6 In cells / mL.

[0096] In one embodiment, the formulation may include a buffer, such as neutral buffered saline, sulfate buffered saline, etc., a carbohydrate, such as glucose, mannose, sucrose, or dextran, mannitol, a protein, polypeptide, or amino acid, such as glycine, an antioxidant, a chelating agent, such as EDTA or glutathione, an adjuvant (e.g., aluminum hydroxide), and a preservative. The formulations of the invention are preferably prepared for intravenous administration.

[0097] therapeutic use The present invention also provides the use of the CD19-targeting universal CAR-T cells of the first aspect of the invention and a pharmaceutical composition according to the third aspect of the invention for the manufacture of a pharmaceutical composition or formulation for preventing and / or treating cancer, and for treating and / or preventing cancer.

[0098] The cancers include tumors at any stage of progression, including clinical stage I to IV tumors. The cancers may include non-solid tumors (e.g., hematological tumors, such as leukemia and lymphoma) or solid tumors. The types of cancers treated with the CARs of the present invention include, but are not limited to, carcinomas, germ cell tumors and sarcomas, and some leukemias and lymphoid malignancies, benign and malignant tumors, and malignant tumors, such as sarcomas, carcinomas and melanomas. Adult tumors / cancers and childhood tumors / cancers are also included.

[0099] Hematological cancers are cancers of the blood or bone marrow. Examples of hematological (or hematogenic) cancers include leukemia, including acute leukemia (e.g. acute lymphocytic leukemia, acute myelocytic leukemia, acute myelogenous leukemia, and myeloblastic, promyelocytic, myelomonocytic, mononuclear and erythroleukemia), chronic leukemia (e.g. chronic myelocytic (granulocytic) leukemia, chronic myeloid leukemia and chronic lymphocytic leukemia), polycythemia vera, lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma (indolent and severe cases), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, myelodysplastic syndromes, hairy cell leukemia and myelodysplasia.

[0100] Solid tumors do not usually include a cyst or a mass of liquid tissue. Solid tumors may be benign or malignant. Different types of solid tumors are named for the type of cells that form them (e.g., sarcoma, carcinoma, and lymphoma). Examples of solid tumors include fibrosarcoma, myxosarcoma, liposarcoma, mesothelioma, lymphoid malignancies, pancreatic cancer, and ovarian cancer.

[0101] The universal CAR-T cells of the present invention are also useful as vaccines for ex vivo immunization and / or in vivo therapy in mammals, preferably, the mammals being humans.

[0102] For ex vivo immune cell production, at least one of i) expanding the cells, ii) introducing a nucleic acid encoding a CAR into the cells, and / or iii) cryopreserving the cells is performed ex vivo prior to administering the cell production cells to a mammal.

[0103] In vitro cell treatment protocols are known in the art and are discussed more fully below. Briefly, cells are isolated from a mammal (preferably human) and genetically modified (i.e., in vitro transformation or transduction) with a vector expressing a CAR as disclosed herein. The CAR-modified cells can be administered to a mammalian recipient to provide a therapeutic benefit. The mammalian recipient can be a human, and the CAR-modified cells can be autologous, allogeneic, or syngeneic cells for the recipient.

[0104] In addition to cell-based vaccines for in vitro immunization, the present invention also provides compositions and methods for enhancing immune responses to target antigens in a patient in vivo.

[0105] The present invention provides a method of treating a tumor, comprising administering to a subject in need thereof an effective amount of the universal CAR-T cells of the present invention.

[0106] The universal CAR-T cells of the present invention can be administered alone or in combination with diluents and / or other components, such as IL-2, IL-15, IL-17, or other cytokines or cells, as a pharmaceutical composition. Briefly, a pharmaceutical composition of the present invention comprises the target cells described herein, optionally in combination with one or more pharma- ceutical or clinically acceptable carriers, diluents, or excipients. Such compositions may include buffers, such as neutral buffered saline, sulfate buffered saline, carbohydrates, such as glucose, mannose, sucrose, dextran, mannitol, proteins, polypeptides, or amino acids, such as glycine, antioxidants, chelating agents, such as EDTA and glutathione, adjuvants (e.g., aluminum hydroxide), and preservatives. The compositions of the present invention are preferably formulated for intravenous administration.

[0107] The pharmaceutical composition of the present invention can be administered in a form suitable for the disease to be treated (or prevented). The amount and frequency of administration will depend on factors such as the characteristics of the patient's disease, the type of disease, and its severity, and the appropriate dosage will be determined by clinical trials.

[0108] When referring to an "immunologically effective amount," an "antitumor effective amount," an "antitumor effective amount," or a "therapeutic amount," the exact amount of the composition of the present invention to be administered will be determined by a physician, taking into consideration the age, weight, tumor size, degree of infection or metastasis, and individual differences in the disease symptoms of the patient (subject). Typically, the pharmaceutical composition comprising the T cells described herein is administered in an amount of 10 4 ~10 9 Dosage of 10 cells / kg body weight, preferably 105 ~10 7 The compositions of T cells may be administered at doses of 1000 cells / kg body weight, including all integer values ​​within these ranges. The compositions of T cells may be administered at these doses several times. The cells may be administered by injection techniques known in immunotherapy (e.g., Rosenberg et al., New Eng. J. of Med. 319:1676, 1988). The optimal dosage and treatment plan for a particular patient can be determined by one skilled in the medical arts by monitoring the patient's disease status.

[0109] The compositions may be administered to a subject by any convenient means, including aerosolization, injection, oral administration, infusion, implantation or transplantation. The compositions described herein may be administered to a patient subcutaneously, intradermally, intratumorally, intranodal, intraspinal, intramuscular, intravenous (iv) injection, or intraperitoneally or intrapleurally. In another embodiment, the T cell compositions of the invention are preferably administered by iv intravenous injection. The T cell compositions may also be administered directly to a tumor, lymph node or site of infection. (CART cell products may be administered intravenously, primarily by intravenous infusion, or directly to a tumor, lymph node or site of infection.)

[0110] In some embodiments of the invention, the activated and expanded cells, as described herein or by other methods known in the art for expanding T cells to therapeutic levels, are used to administer to a patient in conjunction with (e.g., prior to, concurrently with, or subsequent to) any number of relevant therapeutic procedures, including, but not limited to, other treatments with antiviral therapy, cidofovir, interleukin-2, IFN-γ, other cytotoxic chemotherapeutic agents such as azacitidine (also known as ARA-C), checkpoint inhibitors such as PD-1 antibodies, anti-CTLA-4 antibodies, and drugs that suppress cytokine storm, such as anti-IL-6 receptor tocilizumab, etc. In further embodiments, the T cells of the invention can be used in combination with chemotherapy, radiation, immunosuppressants such as cyclosporine A, azathioprine, methotrexate, mycophenolate mofetil, and antibodies or other immunotherapeutic agents. In further embodiments, the cell compositions of the invention are administered to a patient in combination with (e.g., before, simultaneously with, or after) bone marrow transplantation, chemotherapy, such as fludarabine, external beam radiation therapy (XRT), or cyclophosphamide. For example, in one embodiment, a subject may undergo high-dose chemotherapy followed by a peripheral blood stem cell transplant. In some embodiments, after transplant, the subject receives an infusion of expanded immune cells of the invention. In another embodiment, the expanded cells are administered before or after surgery.

[0111] The dosage of the above treatments administered to a patient will vary depending on the exact nature of the disease being treated and the recipient being treated. The dosage rate administered to a human can be implemented according to accepted practices in the art. Typically, a single treatment or course of treatment will be administered in the amount of 1×10 6 pieces~1×10 10 The universal CAR-DNT cells of the invention can be administered to a patient, for example, by means of intravenous infusion.

[0112] The main advantages of the present invention are:

[0113] 1) The CD19 CAR of the present invention is a humanized chimeric antigen receptor, which has the advantage of being less immunogenic and less likely to cause immune rejection compared to whole mouse-derived chimeric antigen receptors.

[0114] 2) The CAR19-DNT cells of the present invention are a general-purpose immune cell product produced without gene editing, with a simple process and good safety. The involvement of TCR molecules is not required for the tumor killing of DNT cells, and they are not MHC restricted, and do not cause GvHD or HvG. This makes them a general-purpose immune cell product, eliminating the problems of the complicated construction process required for knocking out genes such as TCR, large-scale sequencing, and high off-target rates.

[0115] 3) The method of constructing and amplifying CAR-DNT provided by the present invention allows for large-scale production, reducing production costs. Compared with one-to-one individualized therapy, the production costs of the universal CAR-DNT cell product are significantly lower, reducing the burden on patients.

[0116] 4) The CAR-DNT cells provided by the present invention are not limited by the origin of the patient, and can be expanded on a large scale from immune cells from healthy donors, with better cell activity and the ability to provide immediate treatment to patients. This will solve the current problems of low lymphocyte counts, poor quality and insufficient numbers in patients with advanced tumors during autologous CAR DNT cell therapy.

[0117] The present invention will be further described below with reference to specific examples. It is understood that these examples are only used to illustrate the present invention and do not limit the scope of the present invention. Experimental methods for which no specific conditions are given in the following examples are generally performed according to standard conditions, such as those described in Sambrook et al., "Molecular Cloning: A Laboratory Manual" (New York, Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer's recommended conditions. Unless otherwise stated, percentages and parts are by weight.

[0118] In the present invention, a second generation CD19-CAR is used, which is a humanized CD19 scFv (clone 11) containing the mutation V27G in the CDR1 region of VH, and Figure 2 shows a schematic diagram of the structure of the humanized CD19 CAR construct. The present invention will be described below with reference to examples, but the present invention is not limited to these specific embodiments.

[0119] Example 1: Construction of humanized anti-CD19 FMC63 scFv-41BB-CD3ζ The present invention inserts a humanized CD19-ScFv-CAR construct between the XbaI and EcoRI sites of a lentiviral vector, which contains an insert fragment of humanized CD19 ScFv-41BB-CD3ζ between the XbaI and EcoRI cloning sites.

[0120] 1.1 Humanized CD19 antibodies: VH, VL and scFv sequences In the present invention, a humanized CD19 scFv was obtained from the mouse CD19 FMC63 scFv clone, and its CDR1 mutant was made into a humanized scFv (clone 11). The structure of the humanized CD19 scFv is VL-linked peptide-VH. The linking peptide sequence is GSTSGSGKPGSGEGSTKG (SEQ ID NO: 7).

[0121] In the nucleotide sequence, in bold is the sequence of the humanized CD19 VL (SEQ ID NO:1), in default font is the nucleotide sequence of the VH (SEQ ID NO:2, showing the coding G mutation (ggc) in bold), and in medium italics (SEQ ID NO:3) is the nucleotide sequence encoding the linking peptide sequence GSTSGSGKGPGSGEGSTKG (SEQ ID NO:7).

[0122] Humanized CD19 scFv (SEQ ID NO: 4): VL in bold, VH in default font, CDR regions underlined, mutated position 27 of VH (SEQ ID NO: 6) indicated by a large italic G (V27G of VH).

[0123] In the amino acid sequence, the amino acid sequence of VL is in bold (SEQ ID NO:5), the amino acid sequence of VH is in default font (SEQ ID NO:6), and the amino acid sequence of the connecting peptide is in italics (SEQ ID NO:7).

[0124] The present invention has demonstrated, through a three-dimensional model (FIG. 3) and antigen-antibody binding experiments, that the binding ability of the antibody to the CD19 antigen could be improved by mutating the CDR1 region of the humanized CD19 antibody VH. DIQMTQSPSSLSASVGDRVTITC RASQDISKYL NWYQQKPGKAPKLLIY HTSRLH SGVPSRFSGSGSGTDFLTISSLQPEDFATYYC QQGNTLPY TFGGGTKVEIKGSTSGSGKPGSGEGSTKGQVQLQESGPGLVKPSETLSLTCTVS GGSLPDYGVS WIRQPPGKGLEWIG VIWGSETTYYNSALK SRVTISVDTSKNQFSLKLSSVTAADTAVYYCA KHYYYGGSYAMDY WGQGTLVTVSS (SEQ ID NO:4)

[0125] 1.2 Humanized CD19-CAR sequence The humanized CD19-CAR structure is shown in Figure 2. The humanized scFv CAR sequence was cloned in an EF1a promoter lentiviral vector.

[0126] The following nucleotide sequence is the CD8 lead sequence of humanized CD19ScFv-CD8hinge-TM8-41BB-CD3ζ: The CAR structure contains the human CD8 signal peptide, humanized CD19 scFv (VL-hinge-VH), CD8 hinge, CD8 transmembrane, 41BB costimulatory domain and CD3ζ activation domain (Figure 2).

[0127] CD8 lead sequence-CD19 scFv (VL-linker-VH)-CD8 hinge-CD8 TM-41BB-CD3ζ: <CD8リード> ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCG (SEQ ID NO: 8)

[0128] <Humanized CD19 (VL-linker-VH), clone 11 scFv> (The bolded sequence ggc is the mutant sequence encoding V27G) gatattcagatgacccagagcccgagcagcctgagcgcgagcgtgggcgatcgcgtgacc attacctgccgcgcgagccaggatattagcaaatatctgaactggtatcagcagaaaccg ggcaaagcgccgaaactgctgatttatcataccagccgcctgcatagcggcgtgccgagc cgctttagcggcagcggcagcggcaccgattttaccctgaccattagcagcctgcagccg gaagattttgcgacctattattgccagcagggcaacaccctgccgtatacctttggcggc ggcaccaaagtggaaattaaa ggctccacctctggatccggcaagcccggatctggcgagggatccaccaagggc caggtgcagctgcaggaaagcggcccgggcctggtgaaaccgagcgaaaccctgagcctg acctgcaccgtgagcggcggcagcctgccggattatggcgtgagctggattcgccagccg ccgggcaaaggcctggaatggattggcgtgatttggggcagcgaaaccacctattataac agcgcgctgaaaagccgcgtgaccattagcgtggataccagcaaaaaccagtttagcctg aaactgagcagcgtgaccgcggcggataccgcggtgtattattgcgcgaaacattattat tatggcggcagctatgcgatggattattggggccagggcaccctggtgaccgtgagcagc (SEQ ID NO:15)

[0129] <CD8ヒンジ> ACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGAT (SEQ ID NO: 9)

[0130] <CD8 TM> ATCTACATCTGGGCGCCCCTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGC (SEQ ID NO: 10)

[0131] <4-1BB costimulatory domain> AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG (SEQ ID NO: 11)

[0132] <CD3ζ> AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCTAATAG (SEQ ID NO: 12)

[0133] <EcoRI restriction site> gaattc (SEQ ID NO: 13) The amino acid sequence of the humanized CD19-4-1BB-CD3-CAR protein is as follows (see Figure 3 for the structure of the related construct), where the mutations in CDR1 VH are shown in bold and underlined. MALPVTALLLPLALLLHAARPDIQMTQSPSSLSASVGDRVTITCR ASQDISKYLNWYQQKPGKAPKLLIYHTSRLHSGVPSRFSGSGSGT DFTLTISSLQPEDFATYYCQQGNTLPYTFGGGTKVEIKGSTSGSG KPGSGEGSTKGQVQLQESGPGLVKPSETLSLTCTVSG G SLPDYG VSWIRQPPGKGLEWIGVIWGSETTYYNSALKSRVTISVDTSKNQF SLKLSSVTAADTAVYYCAKHYYYGGSYAMDYWGQGTLVTVSST TTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDI YIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTT QEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNEL NLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKM AEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP PR (SEQ ID NO: 14)

[0134] The nucleotide sequence of the humanized CD19-4-1BB-CD3-CAR protein is as follows: ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCG gatattcagatgacccagagcccgagcagcctgagcgcgagcgtgggcgatcgcgtgacc attacctgccgcgcgagccaggatattagcaaatatctgaactggtatcagcagaaaccg ggcaaagcgccgaaactgctgatttatcataccagccgcctgcatagcggcgtgccgagc cgctttagcggcagcggcagcggcaccgattttaccctgaccattagcagcctgcagccg gaagattttgcgacctattattgccagcagggcaacaccctgccgtatacctttggcggc ggcaccaaagtggaaattaaa ggctccacctctggatccggcaagcccggatctggcgagggatccaccaagggc caggtgcagctgcaggaaagcggcccgggcctggtgaaaccgagcgaaaccctgagcctg acctgcaccgtgagcggc ggcagcctgccggattatggcgtgagctggattcgccagccg ccgggcaaaggcctggaatggattggcgtgatttggggcagcgaaaccacctattataac agcgcgctgaaaagccgcgtgaccattagcgtggataccagcaaaaaccagtttagcctg aaactgagcagcgtgaccgcggcggataccgcggtgtattattgcgcgaaacattattat tatggcggcagctatgcgatggattattggggccagggcaccctggtgaccgtgagcagc ACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGAT ATCTACATCTGGGCGCCCCTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGC AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGC CTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCTAATAG (Sequence number 16)

[0135] Example 2: Lentiviral packaging 293T cells were cultured in a 37℃, 5% CO2 incubator, with DMEM+10% FBS medium. On day 2, when the cells reached 90% confluence, they were co-transduced with the expression plasmid and the packaging plasmid psPAX2, pMD2.0G, and the plasmids mixed at the appropriate molar ratio were placed in a culture vessel, gently shaken to mix evenly, and placed in the incubator. After 48-72 hours, the virus was harvested, and after removing the floating dead 293T cells by centrifugation, the virus-containing medium was filtered, concentrated, purified, aliquoted and frozen at -80℃, and titered.

[0136] Example 3: Production of CAR-19DNT cells 3.1 Collection of human peripheral blood samples 30-400 ml of peripheral blood was collected from healthy donors and placed into sodium heparin-containing tubes.

[0137] 3.2 Production and detection of CAR19-DNT cells 3.2.1 Production of CAR19-DNT cells Method 1: On day 0, CD4 cells were isolated by Rosetting with RBCs using the Rossettsep® kit (Stem Cell Technologies Inc.) according to the manufacturer's instructions. + , CD8 + T cells were depleted. After incubating the blood samples with anti-human CD4 and CD8 depletion reagent markers for 20 min at room temperature, the blood was layered on an equal volume density gradient of Ficoll-Hypaque in a 50 ml centrifuge tube. After centrifugation at 2500 rpm for 25 min, the CD4+ T cells of the PBMCs were already present at the Ficoll / plasma interface. + and CD8 + The cells from which the .DELTA. was removed, i.e., DNT cells, were collected and washed once with 0.9% saline. The obtained DNT cells were then cultured at 75 cm 2 1-6×10 in culture flask 6 The cells were cultured at 37°C and 5% CO2 at 10 cells / ml in AIM-V medium coated with anti-human CD3 monoclonal antibody (clone OKT3) (5-20 μg / ml) and containing gentamicin (60 units / ml), recombinant human interleukin-2 (250 IU / ml), recombinant human interleukin-15 (10 ng / ml), recombinant human interleukin-7 (2 ng / ml), recombinant human interleukin-12 (10 ng / ml), and autologous plasma (20 v%).

[0138] On day 1, the prepared DNT cells were cultured overnight and then infected with lentivirus at an MOI of 5 overnight, after which AIM-V medium was replenished every day or every other day depending on the condition of the cells.

[0139] On day 5, when the DNT cells were sufficiently activated and proliferating, 1-3 × 10 DNT cells were cultured in fresh AIM-V growth medium (containing 60 units / ml gentamicin, 500 IU / ml recombinant human interleukin-2 and recombinant human interleukin-15 (10 ng / ml), recombinant human interleukin-7 (2 ng / ml), recombinant human interleukin-12 (10 ng / ml), and autologous plasma (10 v%)). 6The concentration was adjusted to 100 cells / ml and then amplification culture was carried out.

[0140] On the seventh day, 175 cm 2 Subculture in culture flasks, 1-3 x 10 6 The cells were then cultured at 100 cells / ml for 3 days in AIM-V medium containing gentamicin (60 units / ml), recombinant human interleukin-2 (250 IU / ml), recombinant human interleukin-15 (10 ng / ml), recombinant human interleukin-12 (10 ng / ml) and 50 ng / ml of anti-human CD3 monoclonal antibody.

[0141] On the 10th day, 175 cm 2 The cells in the culture bottle were subcultured into a culture bag, and 1-3 × 10 6 The cells were subsequently cultured at 100 cells / ml for up to 14 days in AIM-V medium containing gentamicin (60 units / ml), recombinant human interleukin-2 (500 IU / ml), recombinant human interleukin-15 (10 ng / ml), recombinant human interleukin-12 (10 ng / ml) and 100 ng / ml of anti-human CD3 monoclonal antibody.

[0142] On day 14, CAR-19 DNT cells were harvested by collecting the cells in a 250 ml conical bottom centrifuge bottle tip, centrifuging at 900×g for 10 min, and washing with saline containing 2.5% human serum albumin (also called "vehicle"). The harvested CAR-19-DNT cells were 0.1-1×10 7 The cells were frozen and stored in liquid nitrogen at a concentration of 10000 cells / mL, which was used as the finished CAR19-DNT cell formulation. After passing quality checks, the product was made available for clinical use.

[0143] Method 2: On day 0, CD4 cells were isolated by Rosetting with RBCs using the Rossettsep® kit (Stem Cell Technologies Inc.) according to the manufacturer's instructions. + , CD8 +T cells were depleted. After incubating the blood samples with anti-human CD4 and CD8 depletion reagent markers for 20 min at room temperature, the blood was layered on an equal volume density gradient of Ficoll-Hypaque in a 50 ml centrifuge tube. After centrifugation at 2500 rpm for 25 min, the CD4+ T cells of the PBMCs were already present at the Ficoll / plasma interface. + and CD8 + The cells from which the .BETA. was removed, i.e., DNT cells, were collected and washed once with 0.9% saline. The separated and purified DNT cells (magnetic beads:DNT cells = 1:1) were uniformly mixed with CD3 / CD28 magnetic beads and then incubated at 75 cm 2 1-6×10 in culture flask 6 Cells / ml were cultured at 37°C and 5% CO2 in AIM-V medium containing gentamicin (60 units / ml), recombinant human interleukin-2 (500 IU / ml), recombinant human interleukin-15 (2 ng / ml), recombinant human interleukin-7 (2 ng / ml), recombinant human interleukin-12 (10 ng / ml) and autologous plasma (20 v%).

[0144] On day 1, the prepared DNT cells were cultured overnight and then infected with lentivirus at an MOI of 5 overnight, after which AIM-V medium was replenished every day or every other day depending on the condition of the cells.

[0145] On the fifth day, the DNT cells in the culture flask were blown to mix uniformly, then passed through a magnetic rack to remove the CD3 / CD28 magnetic beads, and the DNT cells were cultured at 1-3 × 10 in fresh AIM-V growth medium (containing 60 units / ml gentamicin, 500 IU / ml recombinant human interleukin-2 and human interleukin-15 (10 ng / ml), recombinant human interleukin-7 (2 ng / ml), recombinant human interleukin-12 (10 ng / ml), and autologous plasma (10 v%)). 6 The concentration was adjusted to 100 cells / ml and then amplification culture was carried out.

[0146] On the seventh day, 175 cm 2 Subculture in culture flasks, 1-3 x 106 The cells were subsequently cultured for 3 days at 100 cells / ml in AIM-V medium containing gentamicin (60 units / ml), recombinant human interleukin-2 (500 IU / ml), recombinant human interleukin-15 (10 ng / ml), and recombinant human interleukin-12 (10 ng / ml).

[0147] On the 10th day, 175 cm 2 The cells in the culture bottle were subcultured into a culture bag, and 1-3 × 10 6 The cells were subsequently cultured at 100 cells / ml for up to 14 days in AIM-V medium containing gentamicin (60 units / ml), recombinant human interleukin-2 (500 IU / ml), recombinant human interleukin-15 (10 ng / ml), and recombinant human interleukin-12 (10 ng / ml).

[0148] On day 14, CAR-19 DNT cells were harvested by collecting the cells with a 250 ml conical bottom centrifuge bottle tip, centrifuging at 900 × g for 10 min, and washing with saline containing 2.5% human serum albumin (also called "vehicle"). The harvested CAR19-DNT cells were 0.1-1 × 10 7 The cells were frozen and stored in liquid nitrogen at a concentration of 10000 cells / mL, which was used as the finished CAR19-DNT cell formulation. After passing quality checks, the product was made available for clinical use.

[0149] 3.2.2 Detection of phenotype and positive rate of CAR-19 DNT cells On the 8th and 13th days, the DNT expression type and CAR19-DNT positivity rate were detected, respectively. At this time, highly pure DNT cells (purity reached 85% or more, as shown in Figure 4) and CAR19-DNT cells with high hCD19-CAR positivity were obtained. The DNT cells in the culture system were identified using anti-human CD3, CD4, and CD8 antibody markers by flow cytometer (Figure 4). At the same time, they were labeled with anti-humanized CD19 FMC63-CD19 antibody to detect the transduction positivity rate (Figure 4).

[0150] Example 4: Cell killing experiments Hela cells expressing CD19 molecules (Hela-CD19 stable cell line) were constructed as target cells by lentivirus infection, and Hela cells not expressing CD19 were used as target cell control. DNT cells not transduced with CAR-CD19 and CD19CAR-DNT cells transduced with humanized CAR-CD19, collected on days 8 and 13 of culture, respectively, were used as effector cells, with an effector cell to target cell ratio of 2:1, and the killing status was monitored in real time by RTCA (Real-Time Cytotoxicity Assay).

[0151] The results are shown in Figure 5. Compared with DNT cells not transduced with CD19-CAR, CAR19-DNT cells transduced with humanized CD19CAR specifically killed Hela-CD19 cells, and there was no significant difference between the two types of cells in killing CD19-negative Hela cells. This indicated that humanized CAR19-DNT cells specifically targeted Hela-CD19 target cells expressing CD19 antigen (Figure 5). In 5-A, the dynamic killing status was shown in real time by RTCA when the effector cell to target cell ratio was 2:1. After reaching the maximum killing time (18 hours), the real-time quantitative killing results monitored by RTCA are shown in 5-B. Quantitative killing results showed that the specific killing of Hela-CD19 by CAR19-DNT cells was high at 98.52% and 98.10% on days 8 and 13 of culture, respectively (Figure 5-B), and the maximum killing effect continued with the extension of the killing time (Figure 5-A).

[0152] All documents related to the present invention are incorporated herein by reference as if each document were incorporated individually. After reading the above content of the present invention, it will be understood that those skilled in the art can make various changes and modifications to the present invention, and that equivalent forms thereof are within the scope of the claims of the present invention.

Claims

1. A universal CAR-T cell that targets CD19, expressing an exogenous CAR construct, wherein the CAR construct has a structure represented by formula I. L-scFv-H-TM-C-CD3ζ (Formula I) (In the formula, L is either absent or a signal peptide sequence, scFv is an antibody single chain variable region sequence that targets CD19; H is absent or is the hinge region; TM is the transmembrane domain; C is a costimulatory signal molecule; CD3ζ is an intracellular signaling sequence derived from CD3ζ; Each "-" independently represents a connecting peptide or peptide bond connecting each of the above elements; the CD19-targeting universal CAR-T cells are CD19-targeting universal CAR-double negative T cells (CAR19-DNT cells); The scFv comprises a heavy chain variable region (VH) having the amino acid sequence shown in SEQ ID NO:6 and a light chain variable region (VL) having the amino acid sequence shown in SEQ ID NO:5, The TM is a transmembrane domain derived from CD28.

2. The generic CAR-T cell targeting CD19 according to claim 1, characterized in that the TCR in the generic CAR-T cell is knocked out.

3. The general CAR-T cell targeting CD19 described in claim 1, characterized in that the CAR construct has the amino acid sequence shown in SEQ ID NO:

14.

4. A method for producing a universal CAR-DNT cell targeting CD19 according to claim 1, comprising: (i) providing an expression vector containing a nucleotide sequence encoding a CAR construct of formula I; L-scFv-H-TM-C-CD3ζ (Formula I) (In the formula, L is either absent or a signal peptide sequence, scFv is an antibody single chain variable region sequence that targets CD19; H is absent or is the hinge region; TM is the transmembrane domain; C is a costimulatory signal molecule; CD3ζ is an intracellular signaling sequence derived from CD3ζ; Each "-" independently represents a connecting peptide or peptide bond connecting each of the above elements. (ii) providing a DNT cell culture containing at least one DNT cell and transducing the DNT cell with the expression vector of step (i) to obtain the universal CAR-DNT cell targeting CD19 according to claim 1; (iii) detecting reactive CAR-DNT cells obtained in optional step (ii), The scFv comprises a heavy chain variable region (VH) having the amino acid sequence shown in SEQ ID NO:6 and a light chain variable region (VL) having the amino acid sequence shown in SEQ ID NO:5, The method is characterized in that the TM is a transmembrane domain derived from CD28.

5. The method of claim 4, wherein the expression vector is a lentiviral expression vector.

6. The method according to claim 4, characterized in that the polynucleotide sequence shown in SEQ ID NO: 16 is incorporated into the viral expression vector in step (i).

7. 1. A pharmaceutical composition comprising: (a) a universal CAR-T cell targeting CD19 according to claim 1, and (b) a pharma- ceutically acceptable carrier, diluent, or excipient; A composition comprising:

8. A use of the CD19-targeting universal CAR-T cell according to claim 1 for the manufacture of a pharmaceutical composition or formulation for preventing and / or treating cancer.

9. The use according to claim 8, characterized in that the cancer is selected from the group consisting of hematological tumors, solid tumors, or a combination thereof.

Citation Information

Patent Citations

  • Construction method of chimeric antigen receptor double-negative T cell

    CN104789595A

  • New car constructs comprising TNFR2 domains

    WO2020030979A2